Many US Tourists Do Not Know About The Health Risks When Traveling In Poor Countries.
About half of the 30 million Americans who tour each year to lower-income countries be after view about unrealized strength risks before heading abroad, new enquire shows. The survey of more than 1200 international travelers departing the United States at Boston Logan International Airport found that 38 percent were traveling to low- or middle-income nations try vimax. Only 54 percent of those travelers sought condition warning earlier to their trip, and foreign-born travelers were the least fitting to have done so, said the Massachusetts General Hospital researchers.
Lack of disquietude about budding health problems was the most commonly cited reason for not seeking vigour information before departure to a poorer nation. Of those who did effort to find health information about their destination, the Internet was the most common source, followed by primary-care doctors, the chew over authors found.
Showing posts with label general. Show all posts
Showing posts with label general. Show all posts
Monday, June 5, 2017
Sunday, June 4, 2017
Promising Method For Early Diagnosis Of Cancer
Promising Method For Early Diagnosis Of Cancer.
A collaboration of US scientists and hidden companies are looking into a assess that could muster even one stray cancer stall among the billions of cells that circulate in the human bloodstream. The promise is that one day such a test, given soon after a treatment is started, could indicate whether the group therapy is working or not. It might even indicate beforehand which care would be most effective product. The test relies on circulating tumor cells (CTCs) - cancer cells that have isolated from the main tumor and are traveling to other parts of the body.
In 2007, researchers at Massachusetts General Hospital, developed a "microfluidic chip," called CellSearch, which could enumerate the enumerate of rove cancer cells, but that test didn't appropriate scientists to trap whole cells and analyze them. But on Monday, Mass General announced an pact with Veridex LLC, part company of Johnson & Johnson, to sanctum a newer version of the test.
According to the Associated Press, the updated prove requires only a couple of teaspoons of blood. The microchip is dotted with tens of thousands of puny posts covered with antibodies designed to put to tumor cells. As blood passes over the chip, tumor cells different from the pack and adhere to the posts.
A collaboration of US scientists and hidden companies are looking into a assess that could muster even one stray cancer stall among the billions of cells that circulate in the human bloodstream. The promise is that one day such a test, given soon after a treatment is started, could indicate whether the group therapy is working or not. It might even indicate beforehand which care would be most effective product. The test relies on circulating tumor cells (CTCs) - cancer cells that have isolated from the main tumor and are traveling to other parts of the body.
In 2007, researchers at Massachusetts General Hospital, developed a "microfluidic chip," called CellSearch, which could enumerate the enumerate of rove cancer cells, but that test didn't appropriate scientists to trap whole cells and analyze them. But on Monday, Mass General announced an pact with Veridex LLC, part company of Johnson & Johnson, to sanctum a newer version of the test.
According to the Associated Press, the updated prove requires only a couple of teaspoons of blood. The microchip is dotted with tens of thousands of puny posts covered with antibodies designed to put to tumor cells. As blood passes over the chip, tumor cells different from the pack and adhere to the posts.
Subscribe to:
Posts (Atom)